Last reviewed · How we verify
NCT03083951: CMELL
Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL)
NA trial testing Complete mesocolon excision in Colorectal Cancer in 93 participants. Completed in 1 January 2023.
1 June 2019
Quick facts
| Lead sponsor | Pere Planellas Giné |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 93 |
| Start date | 1 September 2017 |
| Primary completion | 1 June 2019 |
| Estimated completion | 1 January 2023 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Complete mesocolon excision
- Conventional locoregional lymphadenectomy
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Sigmoid Cancer — all drugs for Sigmoid Cancer →
Sponsor
Pere Planellas Giné
Who can join
Adults 18 to 79, any sex, with Colorectal Cancer or Sigmoid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A randomized, controlled clinical trial comparing lymphadenectomy with extended inferior mesenteric artery ligation (complete mesocolon excision: which includes lymphoma tissue from the origin of the inferior mesenteric vein) with conventional locoregional lymphadenectomy in patients undergoing laparoscopic sigmoidectomy for sigmoid cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact on defecatory, urinary and sexual function after high-tie sigmoidectomy: a post-hoc analysis of a multicenter randomized controlled trial comparing extended versus standard complete mesocolon excision.
Planellas P, Marinello F, Elorza G, Golda T, et al · · 2023 · cited 1× · PMID 37526748 · DOI 10.1007/s00423-023-03026-9
Verify or expand the search:
- PubMed search for NCT03083951
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Pere Planellas Giné trials
Trials by the same sponsor.
- NCT03107650 — Preoperative Prediction Model of Pathological Outcomes (Mesorectum Quality and Positive Circumferential Resection Margin · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03083951 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pere Planellas Giné
- Last refreshed: 29 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03083951.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing